Presentation and diagnosis of childhood-onset combined pituitary hormone deficiency: A single center experience from over 30 years

Johanna Hietamäki; Juho Kärkinen; Anna-Pauliina Iivonen; Kirsi Vaaralahti; Annika Tarkkanen; Henrikki Almusa; Hanna Huopio; Matti Hero; Päivi J Miettinen; Taneli Raivio

doi:10.1016/j.eclinm.2022.101556

Presentation and diagnosis of childhood-onset combined pituitary hormone deficiency: A single center experience from over 30 years

EClinicalMedicine. 2022 Jul 18:51:101556. doi: 10.1016/j.eclinm.2022.101556. eCollection 2022 Sep.

Authors

Affiliations

¹ Helsinki University Hospital, New Children's Hospital, Pediatric Research Center, Helsinki 00014, Finland.
² Department of Physiology, Medicum Unit, Faculty of Medicine, and Stem Cells and Metabolism Research Program, Research Programs Unit, University of Helsinki, Helsinki 00014, Finland.
³ Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
⁴ Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland.

Abstract

Background: Childhood-onset combined pituitary hormone deficiency (CPHD) has a wide spectrum of etiologies and genetic causes for congenital disease. We aimed to describe the clinical spectrum and genetic etiologies of CPHD in a single tertiary center and estimate the population-level incidence of congenital CPHD.

Methods: The retrospective clinical cohort comprised 124 CPHD patients (48 with congenital CPHD) treated at the Helsinki University Hospital (HUH) Children's Hospital between 1985 and 2018. Clinical data were collected from the patient charts. Whole exome sequencing was performed in 21 patients with congenital CPHD of unknown etiology.

Findings: The majority (61%;76/124) of the patients had acquired CPHD, most frequently due to craniopharyngiomas and gliomas. The estimated incidence of congenital CPHD was 1/16 000 (95%CI, 1/11 000-1/24 000). The clinical presentation of congenital CPHD in infancy included prolonged/severe neonatal hypoglycaemia, prolonged jaundice, and/or micropenis/bilateral cryptorchidism in 23 (66%) patients; despite these clinical cues, only 76% of them were referred to endocrine investigations during the first year of life. The median delay between the first violation of the growth screening rules and the initiation of GH Rx treatment among all congenital CPHD patients was 2·2 years, interquartile range 1·2-3·7 years. Seven patients harbored pathogenic variants in PROP1, SOX3, TBC1D32, OTX2, and SOX2, and one patient carried a likely pathogenic variant in SHH (c.676G>A, p.(Ala226Thr)).

Interpretation: Our study suggests that congenital CPHD can occur in 1/16 000 children, and that patients frequently exhibit neonatal cues of hypopituitarism and early height growth deflection. These results need to be corroborated in future studies and might inform clinical practice.

Funding: Päivikki and Sakari Sohlberg Foundation, Biomedicum Helsinki Foundation, and Emil Aaltonen Foundation research grants.

Keywords: CPHD; Growth sreening; Hypopituitarism; Hypopituitarism etiology; Hypopituitarism genetic; Incidence.